| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
185,611,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
6,246,627 |
Avg
Vol: |
2,897,741 |
| 52
Week Range: |
$23.99 - $23.99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Duvall Martin J |
EVP, CCO |
• • – |
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,333 |
94,081 |
|
- |
|
| Lavidas Athanese |
Director |
• • – |
2016-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
131,631 |
|
- |
|
| Panayiotopoulos Paris |
President and CEO |
• • – |
2016-02-01 |
4 |
B |
$4.91 |
$299,996 |
D/D |
61,099 |
61,099 |
2.81 |
- |
|
| Denner Alexander J |
Director |
• • – |
2016-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
35,165 |
|
- |
|
| Protopapas Anna |
Director |
• • – |
2016-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
23,902 |
23,902 |
|
- |
|
| Riedel Norbert G |
Director |
• • – |
2016-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
121,859 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2016-02-01 |
4 |
AS |
$4.81 |
$70,548 |
D/D |
(14,667) |
141,463 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,333 |
156,130 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2016-02-01 |
4 |
AS |
$4.81 |
$70,517 |
D/D |
(14,667) |
350,052 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,333 |
364,719 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2016-02-01 |
4 |
AS |
$4.81 |
$70,515 |
D/D |
(14,667) |
305,326 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2016-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,333 |
319,993 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2015-12-31 |
4 |
D |
$6.25 |
$1,777,381 |
D/D |
(284,381) |
1,732,111 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2015-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
602,500 |
1,814,239 |
|
- |
|
| Berstein David L |
SVP, Chief IP Counsel |
• • – |
2015-09-28 |
4/A |
AS |
$6.46 |
$32,316 |
D/D |
(5,000) |
235,449 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2015-09-28 |
4/A |
AS |
$6.46 |
$32,316 |
D/D |
(5,000) |
126,797 |
|
- |
|
| Duvall Martin J |
EVP, CCO |
• • – |
2015-09-28 |
4 |
AS |
$6.46 |
$32,317 |
D/D |
(5,000) |
64,748 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2015-09-28 |
4 |
S |
$6.46 |
$32,316 |
D/D |
(5,000) |
126,797 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2015-09-28 |
4 |
AS |
$6.47 |
$32,327 |
D/D |
(5,000) |
109,917 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2015-09-28 |
4 |
AS |
$6.46 |
$56,551 |
D/D |
(8,750) |
289,231 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2015-09-28 |
4 |
AS |
$6.46 |
$35,503 |
D/D |
(5,500) |
122,224 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2015-09-28 |
4 |
AS |
$6.46 |
$56,560 |
D/D |
(8,750) |
334,086 |
|
- |
|
| Berstein David L |
SVP, Chief IP Counsel |
• • – |
2015-09-28 |
4 |
AS |
$6.46 |
$32,316 |
D/D |
(5,000) |
240,449 |
|
- |
|
| Berstein David L |
SVP, Chief IP Counsel |
• • – |
2015-09-24 |
4/A |
OE |
$0.00 |
$0 |
D/D |
10,000 |
240,449 |
|
- |
|
| Duvall Martin J |
EVP, CCO |
• • – |
2015-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
69,748 |
|
- |
|
703 Records found
|
|
Page 3 of 29 |
|
|
